An Open-Label, Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase IV
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Sun Pharma Global FZE
- 23 Jul 2019 Status changed from not yet recruiting to recruiting.
- 29 Mar 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jun 2019.
- 31 Oct 2018 New trial record